Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it ...
Deutsche Bank (ETR:DBKGn) initiated coverage on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) with a Buy rating and set a price target of $31.00. The new assessment comes as Denali's shares are seen ...
Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...
Looking for broad exposure to the Large Cap Growth segment of the US equity market? You should consider the First Trust NASDAQ-100 Equal Weighted ETF (QQEW), a passively managed exchange traded fund ...
In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...
Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...